MX2023005930A - Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. - Google Patents

Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.

Info

Publication number
MX2023005930A
MX2023005930A MX2023005930A MX2023005930A MX2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
lung cancer
antibody
combined pharmaceutical
kinase inhibitor
Prior art date
Application number
MX2023005930A
Other languages
English (en)
Inventor
Tao Liu
Xiquan Zhang
Xunqiang Wang
Ding Yu
Xiaole Zhan
Naiying Wu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023005930A publication Critical patent/MX2023005930A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica combinada de un anticuerpo anti-PD-L1 y un inhibidor de cinasa c-Met para tratar el cáncer de pulmón, y específicamente a una composición farmacéutica combinada de un anticuerpo anti-PD-L1 y N-(4-((7-((1-(ciclopentilamino)ciclopropil)metoxi)-6-metoxiquinol in-4-il)oxi)-3-fluorofenil)-N-(4-fluorofenil)ciclopropan-1,1-dime tilamida para tratar cáncer de pulmón y uso de la composición farmacéutica combinada en el tratamiento de cáncer de pulmón.
MX2023005930A 2020-11-26 2021-11-26 Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. MX2023005930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011350770 2020-11-26
PCT/CN2021/133386 WO2022111618A1 (zh) 2020-11-26 2021-11-26 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物

Publications (1)

Publication Number Publication Date
MX2023005930A true MX2023005930A (es) 2023-05-29

Family

ID=81755321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005930A MX2023005930A (es) 2020-11-26 2021-11-26 Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.

Country Status (3)

Country Link
CN (1) CN116437957A (es)
MX (1) MX2023005930A (es)
WO (1) WO2022111618A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024120483A1 (zh) * 2022-12-08 2024-06-13 正大天晴药业集团股份有限公司 喹诺林化合物治疗卵巢癌的用途
WO2024120520A1 (zh) * 2022-12-09 2024-06-13 正大天晴药业集团股份有限公司 喹诺林化合物治疗小细胞肺癌的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012200204B9 (en) * 2003-09-22 2015-02-26 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof
IL256245B (en) * 2015-06-16 2022-09-01 Merck Patent Gmbh Treatments that combine a pd-l1 antagonist
EP3411065B1 (en) * 2016-02-05 2021-03-31 Orionis Biosciences BV Clec9a binding agents
CN111936467B (zh) * 2018-03-02 2022-02-18 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
JP7471227B2 (ja) * 2018-03-07 2024-04-19 ジェンマブ エー／エス 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用
CN111617243B (zh) * 2019-02-28 2023-12-19 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
CN111973739B (zh) * 2019-05-23 2024-02-13 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途

Also Published As

Publication number Publication date
CN116437957A (zh) 2023-07-14
WO2022111618A1 (zh) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2023005930A (es) Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.
MX2021002804A (es) Terapias de combinacion.
JOP20220142A1 (ar) مثبطات kras g12c
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
PH12019500002A1 (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
IL184791A (en) Gaffitinib-Resistant Cancer Treatment Compounds A method to treat gafitinib-resistant cancer with an EGFR gene t790m using irreversible EGFR inhibitors
MX2023010411A (es) Inhibidores de erbb/btk.
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
MX2021002805A (es) Terapias de combinacion.
NZ609283A (en) Compounds as c-met kinase inhibitors
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
CL2012002739A1 (es) Compuesto (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida; composicion farmaceutica que lo comprende; uso del compuesto para el tratamiento de migraña, dolor neuropático, cancer de mama y glioma.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.